Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2024

Note 7 - Accounts Payable and Accrued Expenses

At June 30, 2024, and December 31, 2023, accounts payable and accrued expenses consisted of the following:


	June 30,		December 31,
($ in thousands)	2024		2023
Accounts payable	$	8,934	$	6,322
Accrued research and development		1,606		4,118
Accrued compensation		778		2,838
Other ⁽¹⁾		1,872		739
Total accounts payable and accrued expenses	$	13,190	$	14,017

⁽¹⁾ Other includes approximately $1.4 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.